Inaktiver Wert

Tobira Therapeutics Inc Aktie Nasdaq

Aktien

Dauer

Zeitraum

Stil

TOBIRA fait gagner plus de 40 000 euros à un investisseur !	26.10.16
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20.10.16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03.10.16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21.09.16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20.09.16

Manager	Titel	Alter	Seit
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	+16,45 %	122 Mrd.
REGENERON PHARMACEUTICALS, INC.	+21,96 %	116 Mrd.
ARGENX SE	+25,50 %	27,03 Mrd.
BIONTECH SE	-20,05 %	20,36 Mrd.
BEIGENE, LTD.	-16,28 %	15,91 Mrd.
GENMAB A/S	-15,96 %	16,43 Mrd.
WUXI APPTEC CO., LTD.	-44,35 %	15,6 Mrd.
SAREPTA THERAPEUTICS, INC.	+63,91 %	14,94 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+2,52 %	13,59 Mrd.